1
|
Yan M, Gouveia AG, Cury FL, Moideen N, Bratti VF, Patrocinio H, Berlin A, Mendez LC, Moraes FY. Practical considerations for prostate hypofractionation in the developing world. Nat Rev Urol 2021; 18:669-685. [PMID: 34389825 PMCID: PMC8361822 DOI: 10.1038/s41585-021-00498-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/23/2021] [Indexed: 02/06/2023]
Abstract
External beam radiotherapy is an effective curative treatment option for localized prostate cancer, the most common cancer in men worldwide. However, conventionally fractionated courses of curative external beam radiotherapy are usually 8-9 weeks long, resulting in a substantial burden to patients and the health-care system. This problem is exacerbated in low-income and middle-income countries where health-care resources might be scarce and patient funds limited. Trials have shown a clinical equipoise between hypofractionated schedules of radiotherapy and conventionally fractionated treatments, with the advantage of drastically shortening treatment durations with the use of hypofractionation. The hypofractionated schedules are supported by modern consensus guidelines for implementation in clinical practice. Furthermore, several economic evaluations have shown improved cost effectiveness of hypofractionated therapy compared with conventional schedules. However, these techniques demand complex infrastructure and advanced personnel training. Thus, a number of practical considerations must be borne in mind when implementing hypofractionation in low-income and middle-income countries, but the potential gain in the treatment of this patient population is substantial.
Collapse
Affiliation(s)
- Michael Yan
- grid.410356.50000 0004 1936 8331Division of Radiation Oncology, Cancer Centre of Southeastern Ontario, Queen’s University, Kingston, Canada
| | - Andre G. Gouveia
- Department of Radiation Oncology, Americas Centro de Oncologia Integrado, Rio de Janeiro, Brazil
| | - Fabio L. Cury
- grid.14709.3b0000 0004 1936 8649Department of Radiation Oncology, Cedars Cancer Centre, McGill University, Montreal, Canada
| | - Nikitha Moideen
- grid.410356.50000 0004 1936 8331Division of Radiation Oncology, Cancer Centre of Southeastern Ontario, Queen’s University, Kingston, Canada
| | - Vanessa F. Bratti
- grid.410356.50000 0004 1936 8331Queen’s University School of Medicine, Department of Public Health Sciences, Kingston, Canada
| | - Horacio Patrocinio
- grid.14709.3b0000 0004 1936 8649Department of Medical Physics, Cedars Cancer Centre, McGill University, Montreal, Canada
| | - Alejandro Berlin
- grid.17063.330000 0001 2157 2938Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Lucas C. Mendez
- grid.39381.300000 0004 1936 8884Department of Radiation Oncology, London Regional Cancer Program, Western University, London, Canada
| | - Fabio Y. Moraes
- grid.410356.50000 0004 1936 8331Division of Radiation Oncology, Cancer Centre of Southeastern Ontario, Queen’s University, Kingston, Canada
| |
Collapse
|
2
|
Kao J, Karwowski P, Pettit J, Barney AK, Atalla C. Multiparametric prostate MRI-based intensity-modulated radiation therapy guided by prostatic calcifications. Br J Radiol 2020; 93:20200571. [PMID: 32846099 DOI: 10.1259/bjr.20200571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVES The optimal technique to administer image-guided radiation therapy for prostate cancer remains poorly defined. This study assessed outcomes after multiparametric prostate MRI-based planning was delivered with image-guided radiation therapy using prostatic calculi observed on cone beam CT (CBCT). METHODS Between January 2015 and December 2017, 94 consecutive patients were treated with CBCT-based image-guided radiation therapy (IGRT) without fiducial markers. MRI was routinely incorporated for target delineation and intraprostatic tumor nodules were boosted to allow reduced doses to normal appearing prostate. The primary endpoint was the prevalence of prostatic calcifications while toxicity and biochemical control were secondary endpoints. RESULTS Median follow-up was 39.7 months with 82% NCCN intermediate to very high risk. Intraprostatic calculi were noted in 68% of patients. The 3-year biochemical control, late grade ≥2 rectal toxicity and late grade ≥2 urinary toxicity rates were 96%, 3 and 7%, respectively. Biochemical control and toxicity were not significantly impacted by the presence of prostatic calculi. CONCLUSION Prostatic calcifications can serve as natural fiducial markers to allow for non-invasive IGRT for prostate cancer with promising early disease control and toxicity outcomes. ADVANCES IN KNOWLEDGE Prostate calcification-guided IGRT is technically feasible.
Collapse
Affiliation(s)
- Johnny Kao
- Department of Radiation Oncology, Good Samaritan Hospital Medical Center, West Islip, New York, United States
| | - Pawel Karwowski
- Department of Radiation Oncology, Good Samaritan Hospital Medical Center, West Islip, New York, United States
| | - Jeffrey Pettit
- Department of Radiation Oncology, Good Samaritan Hospital Medical Center, West Islip, New York, United States
| | - Austin Kevin Barney
- Department of Radiation Oncology, Good Samaritan Hospital Medical Center, West Islip, New York, United States
| | - Christopher Atalla
- Division of Urology, Good Samaritan Hospital Medical Center, West Islip, New York, United States
| |
Collapse
|
3
|
Liang X, Zhao W, Hristov DH, Buyyounouski MK, Hancock SL, Bagshaw H, Zhang Q, Xie Y, Xing L. A deep learning framework for prostate localization in cone beam CT-guided radiotherapy. Med Phys 2020; 47:4233-4240. [PMID: 32583418 PMCID: PMC10823910 DOI: 10.1002/mp.14355] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Revised: 06/11/2020] [Accepted: 06/17/2020] [Indexed: 01/31/2024] Open
Abstract
PURPOSE To develop a deep learning-based model for prostate planning target volume (PTV) localization on cone beam computed tomography (CBCT) to improve the workflow of CBCT-guided patient setup. METHODS A two-step task-based residual network (T2 RN) is proposed to automatically identify inherent landmarks in prostate PTV. The input to the T2 RN is the pretreatment CBCT images of the patient, and the output is the deep learning-identified landmarks in the PTV. To ensure robust PTV localization, the T2 RN model is trained by using over thousand sets of CT images with labeled landmarks, each of the CTs corresponds to a different scenario of patient position and/or anatomy distribution generated by synthetically changing the planning CT (pCT) image. The changes, including translation, rotation, and deformation, represent vast possible clinical situations of anatomy variations during a course of radiation therapy (RT). The trained patient-specific T2 RN model is tested by using 240 CBCTs from six patients. The testing CBCTs consists of 120 original CBCTs and 120 synthetic CBCTs. The synthetic CBCTs are generated by applying rotation/translation transformations to each of the original CBCT. RESULTS The systematic/random setup errors between the model prediction and the reference are found to be <0.25/2.46 mm and 0.14/1.41° in translation and rotation dimensions, respectively. Pearson's correlation coefficient between model prediction and the reference is higher than 0.94 in translation and rotation dimensions. The Bland-Altman plots show good agreement between the two techniques. CONCLUSIONS A novel T2 RN deep learning technique is established to localize the prostate PTV for RT patient setup. Our results show that highly accurate marker-less prostate setup is achievable by leveraging the state-of-the-art deep learning strategy.
Collapse
Affiliation(s)
- Xiaokun Liang
- Department of Radiation Oncology, Stanford University, Stanford, CA 94305 USA
- Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055 China
| | - Wei Zhao
- Department of Radiation Oncology, Stanford University, Stanford, CA 94305 USA
| | - Dimitre H. Hristov
- Department of Radiation Oncology, Stanford University, Stanford, CA 94305 USA
| | | | - Steven L. Hancock
- Department of Radiation Oncology, Stanford University, Stanford, CA 94305 USA
| | - Hilary Bagshaw
- Department of Radiation Oncology, Stanford University, Stanford, CA 94305 USA
| | - Qin Zhang
- Department of Radiation Oncology, Stanford University, Stanford, CA 94305 USA
| | - Yaoqin Xie
- Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055 China
| | - Lei Xing
- Department of Radiation Oncology, Stanford University, Stanford, CA 94305 USA
| |
Collapse
|
4
|
Iocolano M, Blacksburg S, Carpenter T, Repka M, Carbone S, Demircioglu G, Miccio M, Katz A, Haas J. Prostate Fiducial Marker Placement in Patients on Anticoagulation: Feasibility Prior to Prostate SBRT. Front Oncol 2020; 10:203. [PMID: 32175274 PMCID: PMC7056879 DOI: 10.3389/fonc.2020.00203] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2019] [Accepted: 02/06/2020] [Indexed: 12/17/2022] Open
Abstract
Background and Purpose: Fiducial marker placement is required in patients undergoing robotic-based Stereotactic Body Radiotherapy (SBRT) or image-guided radiation therapy (IGRT) for prostate cancer. Many patients take antiplatelet or anticoagulant medication due to other medical comorbidities. They are often required to temporarily discontinue these medications prior to invasive medical procedures as they are prone to bleed. Some patients are unable to discontinue therapy due to an elevated risk of thromboembolic events. The purpose of this study is to report this institution's experience placing fiducial markers in prostate cancer patients who are on chronic antiplatelet or anticoagulant medication. Materials and Methods: From August 2015-March 2019 57 patients on chronic antiplatelet or anticoagulation therapy who were not cleared to stop these medications underwent transrectal ultrasound guided (TRUS) fiducial marker placement for SBRT/IGRT. All patients were monitored by a registered nurse during the procedure for prolonged bleeding that required staff to hold pressure to the area with a 4 × 4 gauze until it resolved. All patients were also called the following day to assess for ongoing bleeding events. Treatment planning CT scan confirmed the ideal geometry of the marker placement. Results: All 57 patients on antiplatelet or anticoagulant medication who underwent fiducial marker placement were discharged home the same day of the procedure. Four patients experienced persistent bleeding that required a nurse to hold prolonged pressure to the area. No patient experienced significant bleeding the following day or any untoward cardiovascular event. Conclusions: This series suggests the use of antiplatelet or anticoagulant medication is not an absolute contraindication to fiducial marker placement in patients undergoing SBRT or IGRT for prostate cancer. These patients should be closely monitored after the procedure for bleeding complications. Practitioners may consider the patient's medical comorbidities, risk factors for thromboembolism, and overall functional status as there is no standardized protocol for discontinuing anticoagulant or antiplatelet therapy for fiducial marker placement.
Collapse
Affiliation(s)
- Michelle Iocolano
- Department of Radiation Oncology, NYU Winthrop Hospital, Mineola, NY, United States.,Stony Brook University School of Medicine, Stony Brook, NY, United States
| | - Seth Blacksburg
- Department of Radiation Oncology, NYU Winthrop Hospital, Mineola, NY, United States
| | - Todd Carpenter
- Department of Radiation Oncology, NYU Winthrop Hospital, Mineola, NY, United States
| | - Michael Repka
- Department of Radiation Oncology, NYU Winthrop Hospital, Mineola, NY, United States
| | - Susan Carbone
- Department of Radiation Oncology, NYU Winthrop Hospital, Mineola, NY, United States
| | - Gizem Demircioglu
- Department of Radiation Oncology, NYU Winthrop Hospital, Mineola, NY, United States
| | - Maryann Miccio
- Department of Radiation Oncology, NYU Winthrop Hospital, Mineola, NY, United States
| | - Aaron Katz
- Department of Urology, NYU Winthrop Hospital, Mineola, NY, United States
| | - Jonathan Haas
- Department of Radiation Oncology, NYU Winthrop Hospital, Mineola, NY, United States
| |
Collapse
|
5
|
La radiothérapie externe guidée par l’imagerie dans le cancer de la prostate ; comment, quand et pourquoi ? Cancer Radiother 2018; 22:586-592. [DOI: 10.1016/j.canrad.2018.06.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2018] [Accepted: 06/29/2018] [Indexed: 12/14/2022]
|
6
|
Li W, Lu L, Stephans KL, Sharma N, Vassil A, Shen ZL, Stockham A, Djemil T, Tendulkar RD, Xia P. Volumetric-based image guidance is superior to marker-based alignments for stereotactic body radiotherapy of prostate cancer. J Appl Clin Med Phys 2018; 19:198-203. [PMID: 29450961 PMCID: PMC5849820 DOI: 10.1002/acm2.12280] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2017] [Revised: 12/15/2017] [Accepted: 01/03/2018] [Indexed: 12/29/2022] Open
Abstract
Purposes The aim of this study was to evaluate a dual marker‐based and soft‐tissue based image guidance for inter‐fractional corrections in stereotactic body radiotherapy (SBRT) of prostate cancer. Methods/Materials We reviewed 18 patients treated with SBRT for prostate cancer. An endorectal balloon was inserted at simulation and each treatment. Planning margins were 3 mm/0 mm posteriorly. Prior to each treatment, a dual image guidance protocol was applied to align three makers using stereoscopic x ray images and then to the soft tissue using kilo‐voltage cone beam CT (kV‐CBCT). After treatment, prostate (CTV), rectal wall, and bladder were delineated on each kV‐CBCT, and delivered dose was recalculated. Dosimetric endpoints were analyzed, including V36.25 Gy for prostate, and D0.03 cc for bladder and rectal wall. Results Following initial marker alignment, additional translational shifts were applied to 22 of 84 fractions after kV‐CBCT. Among the 22 fractions, ten fractions exceeded 3 mm shifts in any direction, including one in the left‐right direction, four in the superior‐inferior direction, and five in the anterior‐posterior direction. With and without the additional kV‐CBCT shifts, the average V36.25 Gy of the prostate for the 22 fractions was 97.6 ± 2.6% with the kV x ray image alone, and was 98.1 ± 2.4% after applying the additional kV‐CBCT shifts. The improvement was borderline statistical significance using Wilcoxon signed‐rank test (P = 0.007). D0.03 cc was 45.8 ± 6.3 Gy vs. 45.1 ± 4.9 Gy for the rectal wall; and 49.5 ± 8.6 Gy vs. 49.3 ± 7.9 Gy for the bladder before and after applying kV‐CBCT shifts. Conclusions Marker‐based alignment alone is not sufficient. Additional adjustments are needed for some patients based kV‐CBCT.
Collapse
Affiliation(s)
- Wen Li
- Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Lan Lu
- Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Kevin L Stephans
- Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Naveen Sharma
- Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Andrew Vassil
- Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Zhilei Liu Shen
- Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Abigail Stockham
- Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Toufik Djemil
- Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Rahul D Tendulkar
- Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Ping Xia
- Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
| |
Collapse
|